Abbvie Inc
Change company Symbol lookup
Select an option...
ABBV Abbvie Inc
GVYB Golden Valley Bank
DHC Diversified Healthcare Trust
MGNI Magnite Inc
INFN Infinera Corp
PRSRW Prospector Capital Equity Warrants 1st Jan 2025 *W EXP 01/01/2025
HYMCW Hycroft Mining Holding Equity Warrant Exp 29th May 2025 *W EXP 05/29/2025
NVOS Novo Integrated Sciences Inc
TEL TE Connectivity Ltd
NOTV Inotiv Inc
Go

Health Care : Biotechnology | Large Cap Value
Company profile

AbbVie Inc. (AbbVie) is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from the AbbVie-owned distribution centers and public warehouses.

Premarket

Last Trade
Delayed
$135.80
0.37 (0.27%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$135.43
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
940

10-day average volume:
6,870,234
940

ABBV's position in the Biotechnology industry

Industry PeersABBVGILDVRTXREGNSGEN

Summary

Company ProfileAbbVie Inc. (AbbVie) is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and...
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral...
Go to GILD summary
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes...
Go to VRTX summary
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines...
Go to REGN summary
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in commercializing ADCETRIS, or brentuximab vedotin, for the...
Go to SGEN summary
52-Week Change

VS. INDUSTRY
-7.58%
22.84%
23.29%
22.84%
37.15%
Market Cap

VS. INDUSTRY
$238.9B
$95.0B
$85.1B
$82.1B
$36.7B
Beta

VS. INDUSTRY
0.5
0.4
0.5
0.2
0.5
Dividend Yield

VS. INDUSTRY
4.37%
3.94%
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
31.95x
17.22x
26.32x
20.33x
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$56.7B
$27.0B
$9.2B
$12.4B
$2.1B
Profit Margin

VS. INDUSTRY
13.38%
20.48%
35.40%
33.81%
-31.55%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
13.33%
-13.86%
65.28%
23.79%
--
Revenue Growth (TTM)

VS. INDUSTRY
0.03%
-1.56%
15.86%
-25.07%
23.18%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.